Boston Scientific Exec Says Expects Top-Line Pressure To Persist Into 2027, Making Revenue, EPS Growth Challenging Excluding Penumbra Deal
https://event.choruscall.com/mediaframe/webcast.html?webcastid=9LDIRx3t
Share
Why It Matters
Boston Scientific says its sales growth will stay slow through 2027. When a company grows slower than hoped, watch to see if new deals or products can turn things around.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.